The long-term patency of arteriovenous (AV) fistulas created for hemodialysis of renal-failure patients is usually measured in months, particularly when polytetrafluoroethylene (PTFE) material is interposed between the artery and vein. This is due to the rapid development of intimal hyperplastic lesions in the anastomosis region of the PTFE graft material with the vein. We studied the proliferative patterns in seven human AV fistulas removed at the time of fistula revision. Cell proliferation was determined by using an antibody to the proliferating cell nuclear antigen (PCNA), and specific cell types were identified by immunochemical reagents for smooth muscle cells, monocytes/macrophages, monocytes, lymphocytes, and endothelial cells. All venous segments exhibited a markedly hyperplastic intima. Vascularization of the intima and media by capillary-sized vessels was found. The main intimal cellular component was smooth muscle. Macrophages were usually seen around microvessels, and many also populated the perigraft region of the adventitia. In contrast to human atherosclerotic lesions, high rates of cell proliferation were observed in these fistulas. PCNA indices (percentage of cells that were PCNA positive [mean±SD]) were as follows: intima 17.7±11.3%, media 24±11.2%, and adventitia 20±11.6%. However, the distribution of PCNA-positive cells was not uniform. Instead, the PCNA index in microvesselcontaining intimal fields was five to six times that of avascular fields (28.9 ±10.6% versus 4.9 ±4.5%, respectively, p< 0.001). Double immunolabeling revealed a large proportion of PCNA-positive microvascular endothelial cells and surrounding pericyte-like smooth muscle cells, a few proliferating macrophages, luminal endothelial cells, and subendothelial smooth muscle cells, as well as smooth muscle cells without visual connection to either microvessels or the lumen. Thus, cell proliferation associated with neovascularization seems to be one of the major mechanisms of human AV fistula failure. 
T he long-term patency of arteriovenous (AV)
fistulas created for hemodialysis of renal-failure patients is limited. In particular, those fistulas created with prosthetic graft materials such as polytetrafluoroethylene (PTFE) have patency rates that are usually measured in months. 1 " 3 Although some failures are due to perioperative acute thromboses, a significant proportion are due to the rapid development of an intimal hyperplastic lesion in the anastomosis region of the PTFE graft material with the vein. 145 Smooth muscle cell proliferation has generally been assumed to be the major mechanism of the graft stenosis. Recently, using an antibody to the proliferating cell nuclear antigen (PCNA), we found a low level of cell patient). The group of patients included two men and five women; their age varied from 34 to 77 years. The PTFE grafts ranged in age from 1 month to 4 years after implantation. These specimens were fixed overnight in methanol/Carnoy's fixative (methanol/chloroform/glacial acetic acid in a 60:30:10 volume ratio), paraffin embedded, and sectioned longitudinally to include PTFE and vein portions on the same section. Depending on the size of the sample, one to two portions of tissue were thus placed in each tissue block (i.e., one block per patient), from which several serial sections were generated for hematoxylin and eosin staining as well as the subsequent immunocytochemistry studies (see below). As control human arterial tissue, seven samples of internal mammary artery (IMA; residual from coronary artery bypass surgery) were obtained and processed in the same way as the AV fistulas (again, one portion per tissue block). As positive tissue controls for PCNA staining for cell proliferation, human tonsil and rat small intestine were used with every run and gave the expected well-localized proliferative pattern (data not shown). These tissues were also similarly used as controls for the cell type-specific antibodies. These studies were approved by the Human Subjects Review Committees at both the University of Washington (Seattle) and the University of Michigan (Ann Arbor).
Immunocytochemistry
Serial sections from each sample were reacted with several antibodies. Anti-PCNA (PC10, DAKO Corp., Carpenteria, Calif., used at a 1:1,000 dilution) immunostaining was performed multiple times with excellent reproducibility. This provided stable cell numbers over a range of antibody dilutions, and the 1:1,000 dilution provided the best signal-to-background staining ratio. As previously described with a different PCNA antibody, 6 "in-house" studies with the current antibody revealed a good correlation with thymidine labeling of rat intestine, and the rat intestine control tissue run with each PCNA immunostaining run always revealed specific nuclear staining localized to the crypt epithelium of the intestinal mucosa (data not shown). The other antibodies used in these tissues were anti-smooth muscle a-actin antibody (1:500 dilution, Boehringer Mannheim Corp., Indianapolis, Ind.) to identify smooth muscle cells, CD68 (DAKO-CD68, KP1, 1:500 dilution, DAKO) to identify macrophages, anti-human leukocyte common antigen (DAKO-LCA, CD45RB, 1:20 dilution, DAKO) for lymphocytes and monocytes, and Ulex europaeus agglutinin I (1:500 dilution, Vector Laboratories, Inc., Burlingame, Calif.) to identify endothelial cells. Additional control immunoreactions on this tissue included the use of normal mouse serum, which gave no staining. Additionally, the various antibodies used (all G immunoglobulins [IgGs]) served as nonspecific IgGstaining controls for each other, and each provided distinctly different patterns (e.g., smooth muscle versus macrophage distributions) and except for the PCNA antibody, did not give nuclear localizations.
Single-label immunocytochemistry was performed as previously described. 6 Briefly, sections were deparaffinized and endogenous peroxidase activity was blocked with hydrogen peroxide for 5 minutes. With 1% bovine serum albumin as the diluent, the primary antibody was applied for 60 minutes. The secondary-antibody incubation (biotinylated anti-mouse antibody, dilution 1:200, or biotinylated anii-Ulex antibody, dilution 1:500, from Vector Laboratories) was for 30 minutes followed by avidin-biotin amplification (ABC Elite kit from Vector Laboratories) for 30 minutes. Incubation with 0.1% 3',3'-diaminobenzidine (Sigma Chemical Co., St. Louis, Mo.), hydrogen peroxide, and nickel chloride at 37°C for 5-10 minutes produced a black reaction product. Nuclear counterstaining was done by using either methyl green for 2 minutes or acridine orange/ safranin O for 45 seconds, followed by section dehydration and coverslip mounting.
For double-labeled immunocytochemistry, the aforementioned protocol was followed when separate cell structures were to be labeled. After the first immunostaining procedure described above (PCNA), the sections were washed copiously in phosphate-buffered saline, and the second primary antibody was applied for 60 minutes. The biotinylated secondary antibody to the second primary antibody was then applied for 30 minutes, followed by another 30-minute incubation in Vectastain ABC-AP reagent (Vector Laboratories), and then developed with the alkaline phosphatase substrate (alkaline phosphatase substrate kit, Vector Laboratories), which produced a blue reaction product. Acridine orange/safranin O counterstain was used to visualize all nuclei in the tissue sections.
Morphometric Analysis
To quantitatively study the distribution of PCNApositive cells, the tissue sections were studied by light microscopy at x400 magnification by using a 200x200-/xm field size defined by an ocular grid. Each tissue section was studied in a defined, raster fashion consisting of nonoverlapping microscopic fields. In the smaller IMA sections these were adjacent fields, whereas in the much larger AV fistula sections, these fields were 1 mm apart. Microscopic fields in the intima, media, and adventitia were scored separately. In intimal fields the presence (or absence) of capillaries, arterioles, and venules (termed "microvessels") was also noted. The total numbers of PCNA-positive and -negative nuclei were then added for intimal, medial, and adventitial fields and expressed as a percentage of total nuclei that were PCNA-positive per vessel region per sample. The average PCNA index per sample was then used to calculate the statistical comparisons of the intimas, medias, and adventitias of the AV fistulas versus the IMA samples, as well as to compare regions within the AV fistulas. With the double-immunolabeled slides, the percentage of PCNA-positive nuclei that were associated with each cell type-specific marker was determined as above, again computing averages on a per-sample basis. Average percentages of PCNA-positive cells for each group of fields were obtained and compared by either Student's t test or one-way analysis of variance.
Results

General Observations
All venous segments as well as adjacent portions of PTFE graft material exhibited a markedly hyperplastic intima. Often the original lumen was nearly completely occluded ( Figure 1 ). Widespread vascularization of the intima, media, and adventitia by capillary-sized vessels was seen. In the media and adventitia, the distribution of microvessels was mostly uniform throughout these structures, whereas in the intima microvessel-containing (vascular) and avascular fields were identified ( Figure   2a ). Nearly one half (45.7±27.5%) of intimal fields contained microvessels. Neovascularization was more prominent near the base of the intima adjacent to the media. Focal hemosiderin deposits were found in the media and adventitia of almost all specimens. Identification of cell types was facilitated by specific immunocytochemical staining. The vast majority of neointimal and medial cells were smooth muscle cells (Figure 2b ). a-Actin-positive cells were also found in the adventitia, preferentially around microvessels. Macrophages (CD68-positive cells) and lymphocytes (CD45RB-positive cells with lymphocyte-like morphology) were ubiquitous, with a tendency to be distributed near microvessels (Figure 2c ) or in close association with the PTFE graft material (Figure 2d) . A large proportion of the cells (about 10% in the intima, 5% in the media, and 50% in the adventitia) were negative for the individual cell type-specific antibodies used (this was also revealed by using a cocktail mixture of all individual antibodies; data not shown). Those cells in the adventitia were most likely fibroblasts, whereas the origin of the medial and intimal nonreactive cell population is not clear.
Cell Proliferation in Human AVFistulas
All seven IMA samples used as examples of nonpathological human vessels were without significant intimal thickening, in agreement with previous reports. In contrast to these control human vessels, high rates of cell proliferation were observed in AV fistulas. Figures 3b-3d and  4) . Analysis of variance demonstrated a significant difference between the PCNA index in all layers of IMAs versus the AV fistulas, while there were no significant differences in PCNA index among the intima, media, and adventitia within the AV fistulas.
The distribution of proliferation-positive cells was, however, not uniform. Instead, the PCNA index in microvessel-containing intimal fields was five to six times that of avascular fields (28.9±10.6 versus 4.9±4.5%, respectively, /?<0.001, by Student's t test; Figures 3b and 5) . This was mostly due to proliferative activity detected in the cells composing the microvessels themselves (presumably endothelial cells and "pericytes" or adjacent smooth muscle cells; see the following paragraph on double-label immunocytochemistry). Often a clustering of PCNA-positive cells was seen adjacent to defects in the PTFE graft material, which were presumed to be sites of needle punctures (data not shown). The level of cell proliferation and the age of the graft at the time of sample removal showed no obvious correlation.
We also performed double-label immunocytochemistry with anti-PCNA and cell type-specific antibodies on AV fistulas to identify the cell types displaying PCNA immunostaining ( Figure 6 and Table 1 ). The pattern of PCNA labeling on these double-labeled slides was the same as that seen with the previously discussed singlelabeled PCNA slides. The overall intimal breakdown of PCNA-positive cells was as follows: 42.0±8.7% endothelial cells, 49.0±6.9% smooth muscle cells, 6.1±3.9% macrophages, and 5.0±5.0% CD45RB-positive cells. Since approximately half of the intimal fields contained microvessels and the overall PCNA index in microvessel-containing intimal fields was much greater than that of avascular fields, the PCNA-positive cell breakdown of microvessel-containing intimal fields was close to that of the intima as a whole. In microvessel-containing intimal fields, the PCNA-positive cell breakdown revealed a large and nearly equal proportion of microvascular endothelial (52.0±5.4%) and surrounding pericyte-like smooth muscle cells (45.0±7.2%), plus a smaller but still significant proportion of proliferating inflammatory cells (7.2±4.7% of CD68-positive cells and 5.9±5.3% of CD45RB-positive cells, respectively). In avascular intimal fields, the great majority of proliferating cells was represented by smooth muscle cells (77.0±12.0%). The proportion of PCNA-positive inflammatory cells was lower than 1%. In the media, PCNA immunoreactivity was also displayed by almost the same proportion of the different cell types as seen in microvessel-containing intimal fields: 44.0±8.7% endothelial cells, 40.0±17.0% smooth muscle cells, 7.7±4.2% macrophages, and 3.6 ±3.4% CD45RB-positive cells. In the adventitia, the proportion of PCNA-positive cells that were endothelial cells was still high (39.0±8.2%), but the proportion of PCNA-positive cells delineated as smooth muscle cells was slightly decreased (23.0±7.7%) compared with the intima and media. At the same time, a higher percentage of the PCNA-positive cells were inflammatory cells (24.0±6.8% macrophages and 8.5±2.8% CD45RB-positive cells) compared with the intima and media.
Discussion
In this report, we used the antibody to the cell cycle-related protein, PCNA, to determine the level of cell proliferation in human AV fistulas. PCNA, also known as cyclin, is an auxiliary protein of mammalian DNA polymerase delta and is a stable cell cycleregulated nuclear protein (synthesized mainly in the S phase but also present in Gi and G 2 phases of the cell cycle) whose presence correlates directly with the proliferative state of normal cells. PCNA is absent or present in only very low amounts in normal nondividing cells and tissues, but it is synthesized in variable amounts by proliferating cells of both normal and transformed origin. This ubiquitous and tightly regulated DNA replication protein is a central component of the pathway(s) leading to DNA replication and cell division. 8 " 11 We have previously correlated our method of PCNA immunostaining with thymidine labeling. 6 In that previous study, using a single dose of tritiated thymidine and performing combined immunocytochemistry and autoradiography on the same sections, we found that essentially all thymidine-labeled cells were also PCNA labeled, both in the rat small intestine and in the injured carotid artery. Several more PCNApositive, thymidine-negative cells were detected but only in those topographic regions showing thymidine labeling (e.g., the injured versus the uninjured carotid artery and among the crypt epithelial cells 6 ). This is in keeping with PCNA's being present not only in the S phase of the cell cycle but also in G! and G 2 phases. PCNA immunostaining is commonly used in surgical pathology analyses of tumor growth states and has been correlated with DNA flow-cytometry measurements of the S phase. 1213 Recently, with the use of an anti-PCNA antibody, a low level of cell proliferation was found in human coronary arteries, both normal and atherosclerotic, 6 with most arteries displaying a 0-1% labeling index but with occasional intimas displaying a labeling index of up to =5%. In the current study, using a similar technique, we found that tissues from recently occluded or severely narrowed AV fistulas exhibited relatively high proliferative indices (up to 29% in the intima, 41% in the media, and 43% in the adventitia) compared with normal and atherosclerotic arteries. The precise mech- anisms responsible for such growth are not clear but could be related to the production and/or release of growth factors in association with the upstream prosthetic graft material. Such an anatomy could easily provide high concentrations of growth factors directly to the graft-vein anastomosis region, which is where the most prominent intimal thickening occurs.
The lack of apparent correlation between AV fistula proliferative index and the age of the graft is interesting but not definitive due to the very small number of samples. Clearly, more samples need to be studied to firmly establish this correlation. It is important to remember that we have studied these specimens at only one time point during their evolution, and thus we may be studying events related to the relatively recent production of clinically significant stenoses or occlusions, as opposed to their previous average growth rates. We have no data on the volume growth rate or composition of the intimas over time in these lesions, and thus episodic versus steady growth patterns remain possibilities. It should also be noted that unlike the coronary arteries that we have previously studied, these fistulas are continually manipulated over time (e.g., dialysis needle insertions every few days, upstream from the vein anastomosis tissues studied), and such continual injury could conceivably promote a continual higher level of proliferative activity than is seen in ordinary, undisturbed atherosclerosis. It is hoped that future studies with noninvasive imaging of these lesions over time will provide better information on the growth patterns of these intimal lesions.
There are a number of potential sources of growth factor activity. Certainly, platelet adhesion and release of several growth factors, including platelet-derived growth factor (PDGF) and transforming growth factor-^ (TGF-/3), are likely to occur on the graft surface. 14 -20 Thrombin activation also occurs on the graft material, and thrombin is a potent mitogen for smooth muscle cells. 21 -23 In this regard, an indwelling aortic catheter with thrombus formation has been associated with increased arterial proliferative activity downstream from the catheter. 24 Alternatively, growth factor production could occur from the cells that are directly associated with the graft material, such as macrophages, which can produce growth factors for smooth muscle and endothelial cells (e.g., PDGF and TGF-0). 25 " 28 Indeed, PDGF gene expression has been reported in association with such PTFE graft material. 29 Additionally, undefined substances able to stimulate proliferation of human arterial smooth muscle cells have been reported in the sera of patients with chronic renal failure; the source(s) of such substances are unclear. 30 Other mechanical and hemodynamic factors, such as mechanical stress to the vein wall, 31 differences in circumferential compliance of the vein and graft materials, 432 high arterial pressure in the vein system, 33 tangential stress, 34 and nonlaminar flow, 35 are variables that have been suggested as important modulators of vascular smooth muscle function. Some of these could produce smooth muscle cell stretch, a stimulus that has been reported to be associated with extracellular matrix formation, 36 -39 which clearly is an important component of the neointima. The elucidation of the importance of these potential growth-promoting features could aid in the design of treatment to prevent the occlusive intimal hyperplasias that are seen.
The distribution of proliferating cells within the AV fistula material was not uniform. Instead, the PCNA index in microvessel-containing intimal fields was five to six times that of avascular fields. Double-label immunocytochemistry with anti-PCNA and cell type-specific antibodies revealed that the vast majority of PCNApositive cells was represented by microvascular endothelial cells and surrounding pericyte-like smooth muscle cells. This close spatial association may be because of possible angiogenic factors in the artery wall (e.g., basic fibroblast growth factor 40 ) and to the possible production of smooth muscle growth factors by endothelial cells. 29 - 41 -46 For example, in human carotid plaques, such microvessels have been found to be a prominent source of PDGF-A and -B mRNA. 47 Our data are also consistent with experimental observations demonstrating the vasa vasorum as the main source of early myointimal thickening in porous PTFE arterial grafts. 48 " 51 Neovascularization of the intima has also been observed in rat vein-to-artery grafts. 52 -53 Given that the time course of the cellular development of the human AV fistula lesion is not known, we do not know when microvessels "arrive" in the media and intima of the AV fistula, and therefore, we cannot clearly delineate the temporal role of microvessels in this process. In ordinary atherosclerosis, neovascularization of the intima is thought to occur relatively late in the development of the plaque, often associated with complications such as thrombus or intraplaque hemorrhage organization. 54 " 58 Such microvessels are also thought to come primarily from the adventitial vasa vasorum, although occasional origin from the arterial lumen has been suggested. The rare presence of hemosiderin deposits in our material indicates that some thrombus or hemorrhage organization did occur at some time in these specimens, and early fibrin deposition has been previously described. 1 - 31 The finding of rare hemosiderin deposits in the current study and not in our previous report 1 may be a reflection of more extensive microscopic analysis in the current study. Thus, in AV fistulas, neovascularization of the intima could be the mechanism of either the beginning of formation of myointimal thickening or the progression of an already established neointima. In any case, neovascularization appears to play a major role in intimal hyperplasia, at least in clinically stenotic human AV fistulas.
Of further interest is the detection of cell proliferation among monocyte/macrophage cells and perhaps lymphocytes, as was described earlier in human atherosclerotic plaques. 6 PCNA-positive inflammatory cells were also closely associated with the microvessels. Macrophages are able to stimulate neovasculogenesis both directly, by releasing angiogenic substances such as angiotropin 59 This suggests a potential positive feedback between proliferation of endothelial cells, smooth muscle cells, and macrophages. Macrophages as well as endothelial cells can also stimulate proliferation of surrounding smooth muscle cells because of synthesis and release of growth factors such as PDGF, macrophage-derived heparin-binding growth factor, and TGF-/3. 25 -27 At the same time, T cells as a source of interferon gamma may play the role of a negative regulator of both neovasculogenesis and myointimal growth. In summary, intimal hyperplasia is one of the major mechanisms of human hemodialysis fistula failure. This neointima is characterized by the presence of significant cell proliferation in association with neovascularization. An understanding of the growth factors involved in intimal proliferation may lead to effective methods for preventing this and possibly other forms of vascular stenosis.
